209 related articles for article (PubMed ID: 10373167)
1. Universal HIV screening of pregnant women in England: cost effectiveness analysis.
Postma MJ; Beck EJ; Mandalia S; Sherr L; Walters MD; Houweling H; Jager JC
BMJ; 1999 Jun; 318(7199):1656-60. PubMed ID: 10373167
[TBL] [Abstract][Full Text] [Related]
2. Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. Implications for HIV screening.
Mauskopf JA; Paul JE; Wichman DS; White AD; Tilson HH
JAMA; 1996 Jul; 276(2):132-8. PubMed ID: 8656505
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of universal compared with voluntary screening for human immunodeficiency virus among pregnant women in Chicago.
Immergluck LC; Cull WL; Schwartz A; Elstein AS
Pediatrics; 2000 Apr; 105(4):E54. PubMed ID: 10742375
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of mandatory compared with voluntary screening for human immunodeficiency virus in pregnancy.
Myers ER; Thompson JW; Simpson K
Obstet Gynecol; 1998 Feb; 91(2):174-81. PubMed ID: 9469271
[TBL] [Abstract][Full Text] [Related]
5. The cost effectiveness of universal antenatal screening for HIV in New Zealand.
Bramley D; Graves N; Walker D
AIDS; 2003 Mar; 17(5):741-8. PubMed ID: 12646798
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness estimates for antenatal HIV testing in the Netherlands.
Rozenbaum MH; Verweel G; Folkerts DK; Dronkers F; van den Hoek JA; Hartwig NG; de Groot R; Postma MJ
Int J STD AIDS; 2008 Oct; 19(10):668-75. PubMed ID: 18824618
[TBL] [Abstract][Full Text] [Related]
7. Universal antenatal human immunodeficiency virus (HIV) testing programme is cost-effective despite a low HIV prevalence in Hong Kong.
Lee PM; Wong KH
Hong Kong Med J; 2007 Jun; 13(3):199-207. PubMed ID: 17548908
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of strategies to reduce mother-to-child HIV transmission in Mexico, a low-prevalence setting.
Rely K; Bertozzi SM; Avila-Figueroa C; Guijarro MT
Health Policy Plan; 2003 Sep; 18(3):290-8. PubMed ID: 12917270
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-Saharan Africa.
Marseille E; Kahn JG; Saba J
AIDS; 1998 May; 12(8):939-48. PubMed ID: 9631148
[TBL] [Abstract][Full Text] [Related]
10. Preventing perinatal transmission of HIV--costs and effectiveness of a recommended intervention.
Gorsky RD; Farnham PG; Straus WL; Caldwell B; Holtgrave DR; Simonds RJ; Rogers MF; Guinan ME
Public Health Rep; 1996; 111(4):335-41. PubMed ID: 8711101
[TBL] [Abstract][Full Text] [Related]
11. [Pharmaco-economic evaluation of mandatory HIV-screening in pregnancy; a cost-efficacy analysis in Amsterdam].
Postma MJ; van den Hoek JA; Beck EJ; Heeg B; Jager JC; Coutinho RA
Ned Tijdschr Geneeskd; 2000 Apr; 144(16):749-54. PubMed ID: 10812443
[TBL] [Abstract][Full Text] [Related]
12. National and provincial estimated costs and cost effectiveness of a programme to reduce mother-to-child HIV transmission in South Africa.
Wilkinson D; Floyd K; Gilks CF
S Afr Med J; 2000 Aug; 90(8):794-8. PubMed ID: 11022629
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care.
Mrus JM; Tsevat J
Med Decis Making; 2004; 24(1):30-9. PubMed ID: 15005952
[TBL] [Abstract][Full Text] [Related]
14. Who should be screened for HIV infection? A cost-effectiveness analysis.
McCarthy BD; Wong JB; Muñoz A; Sonnenberg FA
Arch Intern Med; 1993 May; 153(9):1107-16. PubMed ID: 8481077
[TBL] [Abstract][Full Text] [Related]
15. [A comparison of three screening strategies for prevention of perinatal HIV infection in Colombia: a decision analysis model].
Gómez M
Rev Panam Salud Publica; 2008 Oct; 24(4):256-64. PubMed ID: 19133174
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness analysis of antenatal HIV screening in United Kingdom.
Ades AE; Sculpher MJ; Gibb DM; Gupta R; Ratcliffe J
BMJ; 1999 Nov; 319(7219):1230-4. PubMed ID: 10550083
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of expanded antenatal HIV testing in London.
Postma MJ; Beck EJ; Hankins CA; Mandalia S; Jager JC; de Jong-van den Berg LT; Walters MD; Sherr L
AIDS; 2000 Oct; 14(15):2383-9. PubMed ID: 11089627
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of voluntary intrapartum rapid human immunodeficiency virus testing for women without adequate prenatal care.
Grobman WA; Garcia PM
Am J Obstet Gynecol; 1999 Nov; 181(5 Pt 1):1062-71. PubMed ID: 10561619
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African Developing country setting.
Mansergh G; Haddix AC; Steketee RW; Nieburg PI; Hu DJ; Simonds RJ; Rogers M
JAMA; 1996 Jul; 276(2):139-45. PubMed ID: 8656506
[TBL] [Abstract][Full Text] [Related]
20. The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States.
Zaric GS; Bayoumi AM; Brandeau ML; Owens DK
J Acquir Immune Defic Syndr; 2000 Dec; 25(5):403-16. PubMed ID: 11141240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
